Jeffrey Thomas Elliott, CFA Joins Exagen’s Board of Directors
Jeff Elliot adds relevant experience to Exagen’s Board of Directors as a former diagnostics analyst at Robert W. Baird & Co. and as the current CFO of Exact Sciences
SAN DIEGO, CA & ALBUQUERQUE, NM, March 26, 2019 (GLOBE NEWSWIRE) — Exagen Inc., an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by
enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that Jeff Elliott is joining Exagen’s Board of Directors.
Mr. Elliott currently serves as Chief Financial Officer at Exact Sciences where he leads all elements of the company’s finance function, including accounting, financial reporting, planning and analysis, internal audit, investor relations, treasury, commercial and operational data analytics, and risk management. Previously, Mr. Elliott was the Vice President of Strategy and Business Development, where he advanced the company’s corporate strategy and efforts in developing new business partnerships to strengthen growth.
Before joining Exact Sciences, Mr. Elliott was the Senior Analyst, Life Science Tools and Diagnostics at Robert W. Baird & Co., where he led company and industry research, built financial models, and issued stock recommendations to support institutional clients’ investment decisions.
“Jeff brings tremendous capabilities as both a former analyst and a current CFO in one of the top diagnostic companies in the US” stated Ron Rocca, CEO of Exagen Inc. who continued, “He has a track record of success in contributing to the sustainable growth of organizations. His leadership in heading up our audit committee adds discipline and structure and strengthens our Board of Directors. Furthermore, his insights on value drivers will assist us in our development of healthcare economic outcomes and analytical validation.”
“I look forward to working with the other Exagen board members and the management team during this exciting time in the company’s growth. Exagen’s commitment to being patient-focused and discovery-driven creates a very positive culture and sets the stage for continued growth,” said Mr. Elliott.
About Exagen Inc.
We are dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. We have developed and are commercializing a portfolio of innovative testing products under our AVISE brand, several of which are based on our proprietary CellBound Complement Activation Products, or CB-CAPs, technology. CB-CAPs assess the activation of the complement system, a biological pathway that is widely implicated across many autoimmune and autoimmune-related diseases, including systemic lupus erythematosus, or SLE. Our goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA. Our strategy includes leveraging our portfolio of testing products to market therapeutics through our sales channel and targeting the approximately 5,000 rheumatologists across the United States. Our business model of integrating testing products and therapeutics positions us to offer targeted solutions to rheumatologists and, ultimately, better serve patients. For more information, visit www.exagen.com.